Tag Archives: FOMX

Top 5 Undervalued Stocks To Own For 2019

Willamette Valley Vineyards (NASDAQ: WVVI) is a nano-cap winery located in Turner, Oregon. The company produces various mid end, premium, and ultra-premium wines including the Pinot Noir, Chardonnay, Pinot Gris, Ros茅 and Riesling varieties. We usually cover tech stocks but we are big fans of wine and even bigger fans of undervalued stocks; WVVI certainly fits the bill for both. WVVI has enjoyed tremendous average sales and EBITDA growth of 12.8% and 16% respectively for the past 3 years. During the same time period, investors have been met with a modest stock growth of 23.75% from $6.10 to $8 currently. With a market cap of only $40 million and a fair P/E of 22, we believe there is still undiscovered potential for this profitable company and its drought-free wine business.

The Economy of Wine

In the past 6 years, United States wine consumption has seen healthy growth from 336.3 million 9 liter cases in 2010 to 383.9 million 9 liter cases in 2015, This resulted in the total retail value of wine increasing from $46.5 billion in 2010 to $55.8 billion in 2015, a significant 20% growth rate. According to a recent report by goodfruits.com, this growth trend continued in 2016 as “September U.S. wine sales rose from $3.3 billion to $3.7 billion, helping set an annual pace to boost the industry’s overall retail value for the 11th consecutive year”. The prior three 5 year periods has seen total retail value increase by 8.8 billion (2001-2005), 5 billion (2006-2010) and 7.2 (2011-2015). We expect the wine market retail value to grow 1.5% (average growth of the last 3 years) in 2017 and surpass $62 billion by 2020. This growth in wine consumption is further fueled by the inauguration of Donald Trump, whose victory has left many oppositions drinking to a stupor. Under these conditions, we believe specialize vineyards like WVVI are going to earn steady and growing profits for years to come.

Top 5 Undervalued Stocks To Own For 2019: Foamix Pharmaceuticals Ltd.(FOMX)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Press coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.4298608245084 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Top 5 Undervalued Stocks To Own For 2019: PJT Partners Inc.(PJT)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on PJT Partners (PJT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Own For 2019: NovoCure Limited(NVCR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Novocure (NVCR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Feroldi]

    After the company announced details of its phase 3 INNOVATE-3 trial at theAmerican Society of Clinical Oncology (ASCO) annual meeting, shares ofNovoCure (NASDAQ:NVCR), a red-hot medical device companyfocused on cancer, fell as much as12% in early morning trading today. Shares were down about 10% as of 10:30 a.m. EDT.

  • [By Ethan Ryder]

    NovoCure (NASDAQ:NVCR) Director Gabriel Leung sold 80,000 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $28.83, for a total value of $2,306,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

  • [By Chris Lange]

    Novocure Ltd. (NASDAQ: NVCR) announced results from its Phase 3 INNOVATE trial of TTFields in platinum-resistant ovarian cancer. There were no major surprises, except study size is larger than some investors expected, which is not concerning. INNOVATE-3 is set to start later this year and as previously announced will enroll patients with recurrent platinum-resistant ovarian cancer.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on NovoCure (NVCR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Own For 2019: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Todd Campbell]

    Surprising and market-moving information often comes out of the annual American Society of Clinical Oncologists (ASCO) meeting, and so far, ASCO18 hasn’t disappointed. From bluebird bio’s (NASDAQ:BLUE) great-but-not-good-enough results in multiple myeloma to Loxo Oncology’s (NASDAQ:LOXO) stellar results in RET-fusion cancers to Nektar Therapeutics (NASDAQ:NKTR) head-scratching data,here are some quick takes on the data released this weekend.

  • [By Stephan Byrd]

    TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Trading Down 7%” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at www.tickerreport.com/banking-finance/3362849/nektar-therapeutics-nktr-trading-down-7.html.

  • [By Ethan Ryder]

    Nektar Therapeutics (NASDAQ:NKTR) has been given a consensus recommendation of “Buy” by the fifteen ratings firms that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $85.09.

Top 5 Undervalued Stocks To Own For 2019: LightPath Technologies, Inc.(LPTH)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares rose 14.1 percent to $3.65 in the pre-market trading session after reporting 2017 year-end results.
    LightPath Technologies, Inc. (NASDAQ: LPTH) rose 13.3 percent to $2.43 in pre-market trading after reporting a third-quarter earnings beat.
    MYnd Analytics, Inc. (NASDAQ: MYND) rose 10.5 percent to $3.49 in pre-market trading. MYnd Analytics reported a Q2 net loss of $2.7 million on revenue of $459,900.
    SORL Auto Parts, Inc. (NASDAQ: SORL) shares rose 8.4 percent to $5.68 in pre-market trading after reporting upbeat Q1 results.
    Famous Dave's of America, Inc. (NASDAQ: DAVE) shares rose 7.7 percent to $8.40 in pre-market trading after the company reported upbeat earnings for its first quarter on Monday.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 7.5 percent to $6.45 in pre-market trading after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data.
    Mimecast Ltd (NASDAQ: MIME) rose 6.5 percent to $43.50 in pre-market trading following a first-quarter sales beat.
    Boxlight Corporation (NASDAQ: BOXL) rose 6 percent to $12.50 in pre-market trading after surging 77.44 percent on Monday.
    Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares rose 6 percent to $26.05 in pre-market trading after climbing 3.58 percent on Monday.
    PPDAI Group Inc. (NASDAQ: PPDF) rose 4.7 percent to $7.20 in pre-market trading following Q1 results.
    Xunlei Limited (NASDAQ: XNET) rose 4.1 percent to $13.88 in pre-market trading after gaining 2.54 percent on Monday.
    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares rose 4.5 percent to $21.73 in pre-market trading. Mizuho upgraded Valeant from Neutral to Buy.
    Bovie Medical Corporation (NYSE: BVX) rose 4.1 percent to $3.80 in pre-market trading after reporting a first-quarter sales beat.
    Myomo, Inc. (NYSE: MYO) rose 3.4 percent to $4.00 in pre-market trading after jumping 23.25 percent o
  • [By Joseph Griffin]

    Headlines about LightPath Technologies (NASDAQ:LPTH) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LightPath Technologies earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 46.9867601112654 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.